natgillin/translations-raw huggingface dataset:
Dette skal tages i betragtning, hvis kombinationsbehandling med pioglitazon og Liprolog overvejes.
This should be kept in mind if treatment with the combination of pioglitazone and Liprolog Mix25 is considered.
Dette skal tages i betragtning, hvis kombinationsbehandling med pioglitazon og Liprolog overvejes.
This should be kept in mind if treatment with the combination of pioglitazone and Liprolog Mix50 is considered.
Dette skal tages i betragtning, hvis patienten er på saltbegrænset kost.
This should be taken into account in patients on a sodium controlled diet.
Dette skal tages med i betragtning for patienter, der er på kontrolleret natriumdiæt.
Patients on a controlled sodium diet must take this into consideration.
Dette skal tages med ind i overvejelserne hos patienter, som er på kontrolleret natriumkost.
To be taken into consideration by patients on a controlled sodium diet.
Dette skal tages med ind i overvejelserne ved patienter, som er på natriumfattig kost.
To be taken into consideration for patients on a controlled sodium diet.
Dette skal undersøges af din læge. hvis du har aktiv livmoderkræft.
This must be investigated by your doctor. if you have active uterine cancer.
Dette sker automatisk på grund af et vakuum i hætteglasset med pulver.
This happens automatically because of a vacuum in the powder vial.
Dette sker fortrinsvis via CYP2C8, selvom andre isoformer kan være involveret i mindre grad.
This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree.
Dette sker fortrinsvis via cytochrom P450 2C8, selvom andre isoformer kan være involveret i mindre grad.
This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree.
Dette sker fortrinsvis via cytokrom P450 2C8, selvom andre isoformer kan være involveret i mindre grad.
This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree.
Dette sker hos nogle mennesker med fremskreden hiv-infektion (aids), som tidligere har haft hiv- relaterede infektioner.
This happens in some people with advanced HIV infection (AIDS) and who have had HIV related infections before.
Dette sker især hos patienter, hvis nyrer ikke fungerer ordentligt.
This particularly happens in patients whose kidneys are not working properly.
Dette sker ved at sænke den totale mængde af kolesterol, LDL- kolesterol, fedtholdige stoffer (triglycerider) og apo-B (en del af LDL) i blodet. øge mængden af det "gode" kolesterol (HDL-kolesterol) og apo-A-I (en del af HDL).
It does this by lowering the levels of total cholesterol, LDL cholesterol, fatty substances called triglycerides and apo B (a part of LDL) in the blood; to raise levels of ‘good’ cholesterol (HDL cholesterol) and apo A-I (a part of HDL).
Dette sker ved, at stoffet bindes til og blokerer nogle enzymer, der kaldes penicillinbindende protein-transpeptidaser, og som medvirker i de afsluttende trin i opbygningen af bakteriernes cellevæg.
It does so by binding and blocking some enzymes called penicillin-binding protein transpeptidases involved in the last steps of bacterial cell wall production.
Dette sker, når signalmolekyler binder sig til receptorer på T-cellernes overflade.
This happens when signal molecules attach to receptors on the surface of the T cells.
Dette sker, når spidsen af dit kateter bliver sat fast i eller er i meget tæt kontakt med din lever.
This happens when the tip of your catheter is fixed or in very close proximity to your liver.
Dette sker, når visse molekyler binder sig til receptorer på T- cellernes overflade.
This happens when certain molecules attach to receptors on the surface of the T cells.
Dette skete efter en gennemgang af data, som blev tilgængelige efter lægemidlets godkendelse, herunder data fra PALLAS- undersøgelsen.1
This followed a review of data that became available since its authorisation including data from the PALLAS study.1
Dette skulle hjælpe til beskyttelse af miljøet.
These measures should help to protect the environment.
Dette skulle lede til en forbedring af sikkerheden og effektiv anvendelse af Cerezyme.
This should lead to improvement in the safe and effective use of Cerezyme.
Dette skyldes den aftagende virkning af levodopa, hvor patienten oplever pludselige skift mellem "on-perioder", hvor patienten kan bevæge sig, og "off-perioder", hvor patienten har svært ved at bevæge sig.
They are linked to a reduction in the effect of levodopa, when the patient experiences sudden switches between being ‘on’ and able to move, and being ‘off’ and having difficulty moving about.
Dette skyldes den alfa-mimetiske virkning af pseudoephedrinsulfat, i kombination med andre vasokontriktorer som bromocriptin, pergolid, lisurid, cabergolin, ergotamin, dihydroergotamin eller andre dekongestanter brugt til næsen enten peroralt eller nasalt (phenylpropanolamin, phenylephrin, ephedrin, oxymetazolin, naphazolin ...).
This is due to the alpha-mimetic activity of pseudoephedrine sulphate in combination with other vasoconstrictors such as bromocripitine, pergolide, lisuride, cabergoline, ergotamine, dihydroergotamine or any other decongestant medicinal product used as a nasal decongestant, either by oral route or by nasal route (phenylpropanolamine, phenylephrine, ephedrine, oxymetazoline, naphazoline…).
Dette skyldes en af perikon induktion af lægemiddelmetaboliserende enzymer.
This is due to the induction of medicinal product metabolising enzymes by St John’s wort.
Dette skyldes medicinens virkemåde, da den forhindrer blodet i at størkne.
the way your medicine works as it prevents the ability of blood clots to form.
Dette skyldes medicinens virkemåde, da den medicinens virkemåde at danne blodpropper.
This is linked to the way your medicine works as it prevents the ability of blood clots to form.
Dette skyldes måden Deres medicin virker på, da den forebygger, at blodet danner blodpropper.
This is linked to the way your medicine works as it prevents the ability of blood clots to form.
Dette skyldes måden din medicin virker på, da den forebygger at blodet danner blodpropper.
This is linked to the way your medicine works as it prevents the ability of blood clots to form.
Dette skyldes måden din medicin virker på, da den forebygger, at blodet danner blodpropper.
This is linked to the way your medicine works as it prevents the ability of blood clots to form.
Dette skyldes måden din medicin virker på, da den forhindrer blodet i at størkne.
This is linked to the way your medicine works as it prevents the ability of blood clots to form.
Dette skyldes produktet og har ingen betydning.
This observation is attributed to presence of product and is not of clinical concern.
Dette skyldes risikoen for en meget sjælden, men alvorlig sygdom (Reyes syndrom).
This is because of the risk of a very rare but serious disease (Reye’s syndrome).
Dette skyldes risikoen for Reyes syndrom, en meget sjælden, men alvorlig sygdom, der kan påvirke hjerne og lever.
This is because of the risk of Reye’s syndrome, a very rare but serious disease that can affect the brain and liver.
Dette skyldes, at behandlingen skal justeres, før barnet begynder behandlingen med EMEND:
This is because their treatment will need to be changed before starting EMEND:
Dette skyldes, at bekæmpelse af bluetongue hører under de nationale veterinærmyndigheder i samråd med Europa-Kommissionen.
This is because control of bluetongue is the responsibility of national veterinary authorities in consultation with the European Commission.
Dette skyldes, at de aktive stoffer i denne medicin udskilles i mælken hos mennesker.
This is because the active substances in this medicine pass into human breast milk.
Dette skyldes, at det ikke vides, om Odomzo bliver udskilt i brystmælk og dermed kan skade barnet (se ”Amning”). hvis du kan blive gravid, men ikke kan eller ikke vil tage de nødvendige forholdsregler mod graviditet, som er angivet i Odomzos program for svangerskabsforebyggelse.
This is because it is not known whether Odomzo can pass into your breast milk and cause harm to your baby (see section “Breast-feeding”). if you are able to become pregnant but are unable or unwilling to follow the necessary pregnancy prevention measures that are listed in the Odomzo Pregnancy Prevention Programme.
Dette skyldes, at det kan påvirke den måde, din krop nedbryder medicinen på du tager medicin mod depression eller antipsykotiske midler, se punktet om ”Brug af anden medicin sammen med PecFent”.
This is because it may affect the way in which your body breaks down the medicine. you take antidepressants or antipsychotics, please refer to the section ‘Other medicines and PecFent’.
Dette skyldes, at din krop måske ikke optager lægemidlet fuldstændigt, hvis det tages sammen med et måltid.
This is because your body may not absorb the medicine completely if taken with food.
Dette skyldes, at disse former for mad gør, at Deres krop ikke kan optage så meget CRIXIVAN og det derfor ikke vil være lige så effektivt.
This is because these stop your body being able to take in as much CRIXIVAN and it will not work as well.
Dette skyldes, at disse typer celler ikke har brug for EGFR og kan fortsætte med at vokse ukontrolleret, selv om EGFR blokeres.
This is because growth of these types of cells does not depend on EGFR and they can continue to grow uncontrollably even when EGFR is blocked.
Dette skyldes, at en given dosis af Toujeo 300 enheder/ml ikke resulterer i den samme mængde insulin i kroppen som samme dosis insulin glargin 100 enheder/ml.
This is because a given dose of Toujeo 300 units/ml does not result in the same amount of insulin in the body at the same dose of the insulin glargine 100 units/ml.
Dette skyldes, at Iclusig kan forårsage, at hepatitis B-infektionen bliver aktiv igen, hvilket undertiden kan være dødeligt.
This is because Iclusig could cause hepatitis B to become active again, which can be fatal in some cases.
Dette skyldes, at lavere eller manglende doser kan øge risikoen for, at hiv bliver resistent over for CRIXIVAN
This is because reducing or missing doses will make it more likely that HIV will become resistant to CRIXIVAN.
Dette skyldes, at lægemidlet kan udskilles i mælken og kan skade det ammede barn alvorligt.
This is because the medicine passes into breast milk andmay seriously harm your breastfed baby.
Dette skyldes, at medicinen kan skade barnet.
This is because pomalidomide is expected to harm the unborn baby.
Dette skyldes, at Odomzo kan medføre skade eller dødsfald for dit ufødte barn (se ”Graviditet”). hvis du ammer.
This is because Odomzo may cause harm or death to your unborn baby (see section “Pregnancy”). if you are breast-feeding.
Dette skyldes, at perikon inducerer lægemiddelmetaboliserende enzymer og/eller transport- proteiner.
This is due to induction of drug metabolising enzymes and/or transport proteins by St. John’s wort.
Dette skyldes, at Revlimid kan påvirke den måde, nogle af de andre lægemidler virker på.
This is because Revlimid can affect the way some other medicines work.
Dette skyldes, at små mængder af lægemidlet kan gå over i modermælken.
This is because small amounts of the medicine can pass into mother’s milk.
Dette skyldes, at små mængder af medicinen kan passere over i mælken.
This is because small amounts of the medicine can pass into the mother’s milk.
Dette skyldes, at små mængder kan udskilles i modermælken.
This is because small amounts may pass into breast milk.
Dette skyldes, at SPRYCEL kan forårsage, at hepatitis B-infektionen bliver aktiv igen, hvilket undertiden kan være dødeligt.
This is because SPRYCEL could cause hepatitis B to become active again, which can be fatal in some cases.
Dette skyldtes primært en reduktion i kardiovaskulære dødsfald og myokardieinfarkter og optrådte hurtigt med en konstant behandlingseffekt over hele behandlingsperioden (se tabel 3 og figur 1).
The benefit was driven by a reduction in CV death and MI and appeared early with a constant treatment effect over the entire treatment period (see Table 3 and Figure 1).
Dette skyldtes snarere, at der var flere patienter, der stoppede behandlingen med Invirase, end forskelle i lægemidlernes virkning.
This was mainly caused by more patients stopping Invirase treatment rather than by any differences in the effectiveness of the medicines.
Dette stabiliserer membranens hvilepotentiale, og kontrollerer neuronets sub-htreshold excitabilitet, så initiering af epileptiforme aktionspotentialer forhindres.
This stabilises the resting membrane potential and controls the sub-threshold electrical excitability in neurons, thus preventing the initiation of epileptiform action potential bursts.
Dette startede generelt i det første år af behandlingen og blev rapporteret hos 30 patienter (7 %).
This occurred generally in the first year of treatment, and was reported in 30 subjects (7%).
Dette statistiske signal blev også bekræftet i Eudravigilance baseret på PRR analyse.
This statistical signal was also confirmed in Eudravigilance, based on PRR analysis.
Dette stemmer overens med den populationsfarmakokinetiske analyse, som viste lavere eksponering for irinotecan og højere eksponering for dets aktive metabolit SN-38 hos asiater end hos hvide.
This is consistent with the population pharmacokinetic analysis that showed a lower exposure to irinotecan and a higher exposure to its active metabolite SN-38 in Asians than in Caucasians.
Dette stemmer overens med fampridins farmakologiske aktivitet.
This is consistent with fampridine’s pharmacological activity.
Dette stof produceres ved hjælp af rekombinant DNA- teknologi, idet der anvendes ovarieceller fra kinesiske hamstere, som er tilført de humane gener for FSH-subunit.
This is produced by recombinant DNA technology, using a Chinese hamster ovary cell line transfected with the human FSH subunit genes.
Dette stof tilhører en gruppe lægemidler, der kaldes ‘monoklonale antistoffer’.
It belongs to a group of medicines called ‘monoclonal antibodies’.
Dette studie bestod af to faser, en placebo- kontrolleret fase efterfulgt af en forud fastsat opfølgningsfase.
This study consisted of two phases, a placebo-controlled phase followed by a pre-planned follow-up phase.
Dette studie bestod af to faser: en placebokontrolleret fase efterfulgt af en planlagt opfølgningsfase.
This study consisted of two phases, a placebo- controlled phase followed by a pre-planned follow-up phase.
Dette studie er et fase-III, randomiseret, dobbeltblindet studie af telbivudin 600 mg givet én gang daglig sammenlignet med lamivudin 100 mg givet én gang daglig i en behandlingsperiode på 104 uger i 332 nukleosid-naive kroniske hepatitis B HBeAg-positive og HBeAg-negative kinesiske patienter.
This study is a phase III, randomised, double-blind study of telbivudine 600 mg once daily compared to lamivudine 100 mg once daily for a treatment period of 104 weeks in 332 nucleoside- naïve chronic hepatitis B HBeAg-positive and HBeAg-negative Chinese patients.
Dette studie har vist, at immunre- sponset mod de syv fælles serotyper var sammenligneligt med det respons, som blev opnået efter en boosterdosis af 7-valent Prevenar.
This study has shown that the immune responses against the 7 common serotypes were comparable to those elicited by a booster dose of 7-valent Prevenar.
Dette studie omfattede patienter over 18 år med hormon-refraktær metastatisk prostatacancer, enten målelig med RECIST-kriterierne eller ikke-målelig sygdom med stigende PSA-niveauer eller forekomst af nye læsioner og en ECOG (Eastern Cooperative Oncology Group) performance status på 0 til 2.
This study included patients over 18 years of age with hormone refractory metastatic prostate cancer either measurable by RECIST criteria or non-measurable disease with rising PSA levels or appearance of new lesions, and Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
Dette studie skal være hensigtsmæssigt til at sammenligne
This study should be appropriate to compare
Dette studie skal være hensigtsmæssigt til at sammenligne hyppigheden af alle dødsfald, større kardiovaskulære hændelser, nydiagnostiserede tilfælde af cancer, hospitalsindlæggelser uanset årsag, hospitalsindlæggelser relateret til luftvejslidelser, selvmord eller hospitalsindlæggelser pga. selvmordsforsøg samt nydiagnostiserede tilfælde af depression, tuberkulose og viral hepatitis B eller C hos roflumilastbehandlede KOL-patienter versus KOL-patienter, der ikke behandles med roflumilast.
This study should be appropriate to compare the incidences of all-cause mortality, major cardiovascular events, new diagnosis of cancer, all-cause hospitalisation, hospitalisation related to respiratory disease, suicide or hospitalisation for suicide attempt, and new diagnosis of depression, tuberculosis or viral hepatitis B or C in roflumilast treated COPD patients compared with COPD patients not treated with roflumilast.
Dette studie undersøgte anvendelsen af kombinationsbehandling med MPR (melphalan 0,18 mg/kg oralt på dag 1-4 af gentagne 28-dages cyklusser, prednison 2 mg/kg oralt på dag 1-4 af gentagne 28- dages cyklusser og lenalidomid 10 mg/dag oralt på dag 1-21 af gentagne 28-dages cyklusser) til induktionsbehandling, op til 9 cyklusser.
This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide 10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles.
Dette studie var et open-label, randomiseret, aktivt kontrolleret (sevelamer-karbonat), parallelgruppe-studie på op til 55 uger.
This study was an open-label, randomised, active-controlled (sevelamer carbonate), parallel group study for up to 55 weeks.
Dette studie viste et øget antal rapporter om hjertesvigt, men det førte ikke til en øget dødelighed istudiet.
This study showed an increase in reports of heart failure, however this did not lead to an increase in mortality in this study.
Dette studie viste, at hverken orale enkeltdoser på 200 mg nintedanib eller gentagne orale doser på 200 mg nintedanib givet to gange daglig i 15 dage forlængede QTcF-intervallet.
In this study single oral doses of 200 mg nintedanib as well as multiple oral doses of 200 mg nintedanib administered twice daily for 15 days did not prolong the QTcF interval.
Dette studies primære endepunkt var investigatorvurderet samlet responsrate (ORR).
The primary endpoint in this study was ORR per investigator assessment.
Dette svarer til 0,6 g/m2/dag hos rotten, hvilket er lidt under det halve af den anbefalede kliniske vedligeholdelsesdosis af cysteamin, dvs.
This is equivalent to 0.6 g/m2/day in the rat, which is slightly less than the recommended clinical maintenance dose of cysteamine, i.e.
Dette svarer til 0,6 g/m2/dag hos rotten, hvilket er mindre end halvdelen af den anbefalede kliniske vedligeholdelsesdosis af cysteamin, dvs.
This is equivalent to 0.6 g/m2/day in the rat, which is less than half the recommended clinical maintenance dose of cysteamine, i.e.
Dette svarer til en afmålt dosis på 200 mikrogram budesonid og 6 mikrogram formoterolfumaratdihydrat.
This is equivalent to a metered dose of 200 micrograms of budesonide and 6 micrograms of formoterol fumarate dihydrate.
Dette svarer til en afmålt dosis på 200 mikrogram budesonid og 6 mikrogram formoterolfumaratdihydrat.
This is equivalent to a metered dose of 400 micrograms of budesonide and 12 micrograms of formoterol fumarate dihydrate.
Dette svarer til en afmålt dosis på 400 mikrogram budesonid og 12 mikrogram formoterolfumaratdihydrat.
This is equivalent to a metered dose of 400 micrograms of budesonide and 12 micrograms of formoterol fumarate dihydrate.
Dette svarer til et injiceret volumen på 0,05 ml.
This corresponds to an injection volume of 0.05 ml.
Dette symbol betyder,  at doseringsknappen er skubbet ind, og at pennen er klar til nulstilling.
This symbol means the dose knob is pushed in and the pen is ready to reset.
Dette syndrom kan ligne kliniske fund på tumorlysesyndrom som hyperuricæmi, hyperkaliæmi, hypocalcæmi, hyperfosfatæmi, akut nyresvigt, forhøjet laktatdehydrogenase (LD) og kan medføre akut respirationssvigt og død.
This syndrome may be associated with some features of tumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphaetemia, acute renal failure, elevated lactate dehydrogenase (LDH) and may be associated with acute respiratory failure and death.
Dette syndrom kan være livstruende.
This syndrome can be fatal.
Dette syndromet bør tages i betragtning hos enhver patient, der indfinder sig med krampeanfald, hovedpine, synsforstyrrelser, konfusion eller ændret mental status.
This syndrome should be considered in any patient presenting with seizures, headache, visual disturbances, confusion or altered mental function.
Dette synes at være relateret til brugen af spray-anordning ved et højere tryk end det anbefalede og/eller i umiddelbar nærhed af vævsoverfladen.
This event appears to be related to the use of the spray device at higher than recommended pressures and/or in close proximity to the tissue surface.
Dette synes dog ikke at være associeret med en reduktion i den kliniske effekt (med hensyn til tid til klinisk definitiv dissemineret sklerose (CDMS), tid til bekræftet EDSS-progression og relapse-frekvens).
However, this did not seem to be associated with a reduction in clinical efficacy (with regard to time to clinically definite multiple sclerosis (CDMS), time to confirmed EDSS progression and relapse rate).
Dette sås 2-24 timer efter administration af idarucizumab, primært efter ≥ 12 timer.
This occurred 2-24 hours after administration of idarucizumab mainly at timepoints ≥12 hours.
Dette sås ikke ved doser ≤20 mg/kg.
This was not seen at doses ≤ 20mg/kg.
Dette sænker blodtrykket i lungerne og giver bedring i symptomerne på CTEPH og PAH.
This helps to lower the blood pressure in the lungs and improve symptoms of CTEPH and PAH.
Dette tab af kropsfedt har vist sig ikke at være fedttab fuldt reversibelt efter ophør med stavudin.
This loss of body fat has been shown to be not fully reversible after discontinuation of stavudine.
Dette tab skyldes skumdannelse, væske der klæber på siderne af hætteglasset og "rest-volumen", som ikke kan udtages.
This fill volume has been established during the development of docetaxel to compensate for liquid loss during preparation of the premix due to foaming, adhesion to the walls of the vial and "dead-volume".
Dette tager 30-45 minutter.
This will take 30-45 minutes.
Dette tager som regel mellem 15 og 30 minutter.
This usually takes between 15 and 30 minutes.
Dette tal bliver et nummer større, hver gang sprayen bruges.
This will go up each time the spray is used.
Dette tal er antallet af injektionssteder og det totale antal sprøjter (hver fyldt med 0,5 ml), som er nødvendigt for at administrere et volumen på 0,5 ml pr. injektionssted til patientens behandling.
This is the number of injection sites and the total number of syringes (each filled with 0.5ml) needed to administer a volume of 0.5ml per injection site for the patient’s treatment.
Dette tal er antallet af injektionssteder og det totale antal sprøjter (hver fyldt med 0,5 ml), som er nødvendigt for patientens behandling.
This is the number of injection sites and the total number of syringes (each filled with 0.5ml) required for the patient’s treatment.
Dette tid-til-hændelse effektmål er stærkt påvirket af det høje antal skift fra IFN+Ara-C-armen til imatinib-armen.
This time-to- event endpoint is strongly affected by the high crossover rate from IFN+Ara-C to imatinib.
Dette trin er hovedsageligt af hensyn til din komfort.
A. This step is primarily for your comfort.
Dette trin kan gentages, indtil du har den rigtige mængde vand til injektionsvæsker i sprøjten.
This step may be repeated until the correct amount of Water for Injections is in the syringe.
Dette trin kan gentages, indtil du har fået den rigtige mængde opløsning op i sprøjten.
This step may be repeated until the correct amount of solution is in the syringe.
Dette tryk nedsætter den iltmængde, der optages af blodet i lungerne, hvilket vanskeliggør fysisk aktivitet.
This pressure reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult.